Thursday, March 13, 2008 - 11:00 a.m. ET; 8:00 a.m. PT
VANCOUVER and SAN DIEGO, March 11 /PRNewswire-FirstCall/ - MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious diseases, will host a conference call and webcast on Thursday, March 13, 2008 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third fiscal quarter ended January 31, 2008 and provide an update on company activities. To participate in the conference call, please dial 416-644-3417 or 1-800-732-0232. The call will be available for replay until March 27, 2008 by calling 416-640-1917 or 1-877-289-8525 and entering the pass code 21263848 followed by the number sign. The live and archived webcast can be accessed through the company's website at http://www.migenix.com for the next 90 days.
MIGENIX is committed to advancing therapy, improving health, and
enriching life by developing and commercializing drugs primarily in the
area of infectious diseases. The Company's programs include drug candidates
for: the prevention of catheter-related infections (Phase III), the
treatment of chronic hepatitis C infections (Phase II and preclinical), the
treatment of dermatological diseases (end of Phase II), the treatment of
serious gram positive bacterial infections (preclinical) and the treatment
of hepatitis B infections (preclinical). MIGENIX is headquartered in
Vancouver, British Columbia, Canada with US operations in San Diego,
California. Additional information can be found at http://www.migenix.com.
James M. DeMesa, M.D.
President & CEO
CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Ext. 233, firstname.lastname@example.org; Dian Griesel, Ph.D., Investor Relations Group, Tel: (212) 825-3210, Theproteam@aol.com
|SOURCE MIGENIX Inc.|
Copyright©2008 PR Newswire.
All rights reserved